Prashanth Thakker, MD
Interventional Cardiology · Saint Louis, MONPI 1467896530
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 80.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $67,014 and has fallen 64.8% since, to $23,612 in 2025. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $394.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$104K
- Shockwave Medical, Inc$11K
- Amgen$5K
- Biotronik Inc.$2K
- Medtronic$2K
- Boston Scientific$2K
- plus $3K from 12 others
Across 11 payments — averaging $3831.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$42K
What the payments were for
- Consulting fees$18,73515%
- Speaking & faculty fees$53,83542%
- Travel & lodging$38,32630%
- Food & beverage$17,72714%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 181 | $103,548 |
| Shockwave Medical, Inc | 19 | $10,875 |
| Amgen | 18 | $4,894 |
| Biotronik Inc. | 16 | $2,465 |
| Medtronic(2 entities) | 33 | $1,915 |
| Boston Scientific | 19 | $1,638 |
| Abiomed | 10 | $1,069 |
| Abbott | 7 | $658 |
| Penumbra, Inc. | 5 | $515 |
| Cardiovascular Systems Inc. | 6 | $308 |
| Siemens Medical Solutions USA, Inc. | 2 | $272 |
| Heartflow, Inc. | 2 | $156 |
| AstraZeneca | 2 | $133 |
| Novo Nordisk | 1 | $112 |
| Teleflex LLC | 1 | $108 |
| Boehringer Ingelheim | 2 | $38 |
| Asahi Intecc USA, Inc. | 1 | $33 |
| Edwards Lifesciences | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (9520) IGT Devices Undivided$45,133
- US Und$33,295
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$10,403
- IGT Devices Und$9,400
- Repatha$4,254
- (R11) US EQ Undivided$3,760
- (6574) Coronary Other$2,220
- (7881) Ultrasound Und$2,165
- (6554) Peripheral Vascular Undivided$1,648
- Impella$948
- ONYX FRONTIER$728
- (BQ9) Coronary IVUS$547
- (6575) Coronary Undivided$496
- Pulsar$464
- Orsiro$464
- Astron; Pulsar; AstronPulsar$464
- PK Papyrus$464
- PRO-Kinetic Energy$464
- Xience Sierra Coronary Stent System$431
- Indigo System$416
How this compares
$128,760 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 101 | $107,193 |
| EntrestoSacubitril/Valsartan | 41 | $37,934 |
| FarxigaDapagliflozin Propanediol | 48 | $36,524 |
| Repatha SureclickEvolocumab | 33 | $22,276 |
| Ezetimibe | 128 | $3,170 |
| Metoprolol Succinate | 137 | $1,643 |
| Atorvastatin Calcium | 176 | $1,379 |
| Rosuvastatin Calcium | 118 | $962 |
| Losartan Potassium | 99 | $769 |
| Spironolactone | 154 | $746 |
| Carvedilol | 147 | $722 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 67 | $679 |
| Lisinopril | 79 | $660 |
| Amlodipine Besylate | 133 | $545 |
| Diltiazem 24hr Er (Xr)Diltiazem Hcl | 15 | $432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $133 | $36,52448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
- Anthony SonnSaint Louis$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.